# Thrombotic Thrombocytopenic Purpura Without Neurological Involvement: A Case Report and Review of the Diagnostic and Treatment Strategies

**Authors:** Kapeel Daive, Jegadis Sreeneyasan

PMC · DOI: 10.7759/cureus.83654 · Cureus · 2025-05-07

## TL;DR

A 48-year-old woman with TTP without neurological symptoms was diagnosed and treated successfully with plasma exchange, highlighting the importance of timely intervention.

## Contribution

This case report emphasizes the diagnostic and treatment approach for TTP without neurological involvement.

## Key findings

- The patient had 0% ADAMTS13 activity and a platelet count of 4 × 10⁹/L, confirming TTP.
- Plasma exchange was effective in treating the patient and preventing end-organ damage.
- Timely diagnosis and treatment are crucial for managing TTP without neurological symptoms.

## Abstract

This case report describes the presentation of thrombotic thrombocytopenic purpura (TTP) without neurological involvement in a 48-year-old woman. TTP is a relatively rare, life-threatening condition that comprises thrombotic microangiopathy (TMA) and enzymatic dysfunction of ADAMTS13 (a disintegrin-like metalloproteinase with thrombospondin motif type 1, member 13, which regulates platelet aggregation). Another similar condition that presents with TMA in adults is atypical hemolytic uremic syndrome. It is challenging to differentiate between the two conditions clinically, especially in the absence of neurological symptoms. However, plasma exchange is the initial lifesaving treatment for both in acute situations. Our patient had a history of bruising, which was evident in clinical examination, without any other positive findings. However, ADAMTS13 activity was 0%, and the platelet count was 4 × 10⁹/L on arrival. Timely investigation and treatment not only saved her life but also reduced end-organ damage. This report provides an overview of the acute presentation of TTP, positive clinical findings, investigations, diagnosis, treatment, and post-treatment outcomes.

## Linked entities

- **Proteins:** ADAMTS13 (ADAM metallopeptidase with thrombospondin type 1 motif 13)
- **Diseases:** thrombotic thrombocytopenic purpura (MONDO:0018896), atypical hemolytic uremic syndrome (MONDO:0016244)

## Full-text entities

- **Genes:** ADAMTS13 (ADAM metallopeptidase with thrombospondin type 1 motif 13) [NCBI Gene 11093] {aka ADAM-TS13, ADAMTS-13, C9orf8, VWFCP, vWF-CP}
- **Diseases:** end-organ damage (MESH:C564816), bruising (MESH:D003288), platelet aggregation (MESH:D001791), TTP (MESH:D011697), hemolytic uremic syndrome (MESH:D006463), Neurological Involvement (MESH:C538190), TMA (MESH:D057049)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12143186/full.md

## References

6 references — full list in the complete paper: https://tomesphere.com/paper/PMC12143186/full.md

---
Source: https://tomesphere.com/paper/PMC12143186